PT Darya-Varia Laboratoria Tbk (DVLA.JK)
- Previous Close
1,435.00 - Open
1,440.00 - Bid --
- Ask --
- Day's Range
1,420.00 - 1,440.00 - 52 Week Range
1,375.00 - 2,110.00 - Volume
17,000 - Avg. Volume
54,494 - Market Cap (intraday)
1.602T - Beta (5Y Monthly) -0.15
- PE Ratio (TTM)
10.92 - EPS (TTM)
130.99 - Earnings Date --
- Forward Dividend & Yield 121.00 (8.46%)
- Ex-Dividend Date Nov 13, 2023
- 1y Target Est
--
PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia. It operates in four segments: Prescription Drugs, Consumer Health Products, Export and Toll Manufacturing Services, and Services. The company provides prescription products in various areas of cardiology, analgesics, gastro-hepatology, dermamedic, somatic, cough and cold, antibiotic, women healthcare, antiparasit, vitamin and food supplements, anti fungal, plastic surgery, general surgery, burn, trauma wound, aesthetic medicine, somatik, ear healthcare, and central nerve systems. It also offers Consumer Health products comprising Skin Nutrition under the Natur-E brand; Respiratory products under the Decolgen, ALLERIN EXPECTORANT, Decolsin, NEOZEP, STOP COLD, SILEX, and HERBABLEND brand names for nasal congestion, cough, as well as breathing issues caused by allergy; multivitamins under the Enervon-C, Enervon Active, Enervon Gold, and Supertin brands; vitamin C under the Vicee brand; and supplement for kids with Zinc and vitamin C under the Imunped brand; Biogesic for various types of pain; Diatabs, a anti diarrhea product; and New Enzyplex to prevent indigestion. In addition, the company offers toll manufacturing services for soft gelatin capsules, and sterile injections and low volume solid products. It also exports its products to Malaysia, Myanmar, the Philippines, Singapore, Vietnam, and Mongolia. The company was founded in 1976 and is headquartered in Jakarta, Indonesia. PT Darya-Varia Laboratoria Tbk is a subsidiary of Blue Sphere Singapore Pte. Ltd.
www.darya-varia.com1,269
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: DVLA.JK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DVLA.JK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DVLA.JK
Valuation Measures
Market Cap
1.60T
Enterprise Value
1.36T
Trailing P/E
10.92
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.85
Price/Book (mrq)
1.14
Enterprise Value/Revenue
0.72
Enterprise Value/EBITDA
6.00
Financial Highlights
Profitability and Income Statement
Profit Margin
7.74%
Return on Assets (ttm)
5.75%
Return on Equity (ttm)
10.42%
Revenue (ttm)
1.89T
Net Income Avi to Common (ttm)
146.34B
Diluted EPS (ttm)
130.99
Balance Sheet and Cash Flow
Total Cash (mrq)
240.04B
Total Debt/Equity (mrq)
0.10%
Levered Free Cash Flow (ttm)
-8B
Company Insights: DVLA.JK
DVLA.JK does not have Company Insights